Pfizer’s stock has dropped 25% from its recent high, raising questions about whether it's a buy at $23. Pipeline failures and ...

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

Pfizer has earned a “Moderate Buy” rating from fifteen research firms, reflecting a mix of cautious optimism and mild ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

Pfizer (NYSE:PFE) recently ended its strategic collaboration with Acepodia and is facing legal challenges related to ...

This is where InvestingPro’s powerful stock screener comes in. Among its many pre-built tools, the “ Cash is King ” screener stands out for investors who prioritize financial strength. It identifies ...

Let’s dig into the relative performance of Corcept (NASDAQ:CORT) and its peers as we unravel the now-completed Q1 branded ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss t ...

The firm maintained an Outperform rating, reflecting optimism about 3SBio’s financial performance. Additionally, Pfizer Netherlands International Finance B.V., a subsidiary of Pfizer, has received an ...

Pfizer, currently trading at $23 and maintaining a strong 7.48% dividend yield, has entered into an agreement with 3SBio to acquire a VEGFxPD-1 bispecific, known as SSGJ-707, for an upfront ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other cheap NYSE stocks. On March 26, Jack Caffrey of JPMorgan Asset Management provided an analysis of ...